Answers are grounded in this paper and cite their sources.
This study reports the synthesis of a novel series of (R)-camphor-based thiosemicarbazones and thiazolidinones derivatives. We obtained the compounds through heterocyclization and Knoevenagel-type condensation reactions, and characterized them by HRMS and NMR spectroscopy. Several derivatives exhibited promising in vitro antiparasitic activity against Leishmania major promastigotes and amastigotes, as well as Toxoplasma gondii tachyzoites. Compound 1 showed activity against L. major amastigotes and promastigotes, with EC₅₀ values of 0.5 and 11.9 µg/mL, respectively. Compounds 2a, 6a, 6b, 5a , and 3a–c were active against L. major promastigotes (EC₅₀ < 10 µg/mL), while 4a–c and 5a–c exhibited antitoxoplasmal activity (EC₅₀ < 11 µg/mL). Molecular docking identified 2a, 3a , and 3b as compounds with multiple interactions with the active site of trypanothione reductase and N-myristoyltransferase. We performed DFT calculations at the B3LYP/6-311 + + G(d,p) level to investigate their optimized geometries and HOMO–LUMO gaps, and used SwissADME to assess their pharmacokinetic properties. The results identify selected (R)-camphor-derived thiazolidinones as promising starting points for further antiparasitic investigation.
No takes yet. Share an insight, caveat, or question.
Ousidi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: